Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’-Reference-Cited by-同舟云学术

Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’

Published:2023-04-25 Issue:8 Volume:48 Page:940-941
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

López Sanz Pablo¹^ORCID,Guzmán Pérez Marta²,Guerrero Ramírez Claudia³,Manso Córdoba Silvia¹,Alfaro Martínez María Encarnación³,Azaña Defez José Manuel¹

Affiliation:

1. Departments of Dermatology

2. Internal Medicine, University General Hospital of Albacete , Albacete , Spain

3. Departments of Dermatology and Internal Medicine, University General Hospital of Albacete , Albacete , Spain

Abstract

The management of patients with paradoxical hidradenitis suppurativa receiving biologic therapy should be individualized, but the treatment of these reactions is mainly based on the discontinuation of the culprit drug taking into account the balance between subsequent risks and benefits.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad160/50514524/llad160.pdf

Reference7 articles.

1. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’;Martora;Clin Exp Dermatol,2023

2. Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab;López Sanz;Clin Exp Dermatol,2023

3. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review;Ruggiero;Biomedicines,2022

4. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases;Faivre;J Am Acad Dermatol,2016

5. A comparison of international management guidelines for hidradenitis suppurativa;Hendricks;Dermatology,2021